Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2114412

Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020

Description:
Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Karenitecin sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU and Japan (seven major markets)
- Analysis and review of Karenitecin including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Karenitecin including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2014-2020 for Karenitecin in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Karenitecin, ovarian cancer, BNP 1350, anti-cancer chemotherapy drug, synthetic silicon-containing agent, camptothecin, anti-neoplastic, Bionumerik, second line treatment for ovarian cancer, second line treatment for stage III and stage IV platinum resistant ovarian cancer, metastatic melanoma, advanced non-small cell lung cancer, small cell lung cancer, colorectal cancer, lymphomas, breast cancer, topoisomerase I, sales forecast, phase III/pipeline, competitors to karenetecin Avastin, Doxil, AMG386, EC145
 
Contents:
1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Ovarian Cancer
2.2 Ovarian Cancer Market
2.3 Epidemiology
2.4 Etiology
2.4.1 Age
2.4.2 Inherited Gene Mutations
2.4.3 A Previous Cancer Diagnosis
2.4.4 Early Menstruation or Late menopause
2.4.5 Family History of Ovarian Cancer
2.5 GlobalData Market Forecasts Report Guidance
3 Ovarian Cancer: Market Characterization
3.1 Ovarian Cancer Market
3.2 Ovarian Cancer Market Forecasts and CAGR
3.3 Drivers for Ovarian Cancer Market
3.3.1 High Incidence
3.3.2 High Mortality Rate
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer
3.3.4 Emergence of Targeted Therapy Drugs
3.3.5 Recurrence of Tumor
3.3.6 Low Initial Diagnosis Rate
4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer
5 Karenitecin
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of Karenitecin
5.4.1 Good Safety Profile
5.4.2 Large Unmet Need
5.4.3 Low Efficacy
5.5 Drug Evaluation
5.5.1 Drug Risk Benefit Score
5.5.2 Intensity of Competition
5.5.3 Sales Forecasts
5.5.4 Target Patient Pool of Karenitecin
5.5.5 Dosing
5.5.6 Market Penetration
5.5.7 Annual Cost of Therapy
5.6 Sales Projections of Karenitecin
6 Ovarian Cancer Market: Appendix
6.1 Market Definitions
6.2 List of Abberiviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources

1.1 List of Tables
Table 1: Ovarian Cancer, Incidences and Mortality, 2008–2030
Table 2: Detailed TNM Classification
Table 3: Drug Risk Benefit Score
Table 4: Annual Cost of Therapy of Karenticin, 2014
Table 5: Karenitecin, Ovarian Cancer, Global, Sales Forecasts ($m), 2014–2020
Table 6: Karenitecin, Ovarian Cancer, The US, Sales Forecasts ($m), 2014–2020
Table 7: Karenitecin, Ovarian Cancer, The UK, Sales Forecasts ($m), 2014–2020
Table 8: Karenitecin, Ovarian Cancer, France, Sales Forecasts ($m), 2014–2020
Table 9: Karenitecin, Ovarian Cancer, Germany, Sales Forecasts ($m), 2014–2020
Table 10: Karenitecin, Ovarian Cancer, Italy, Sales Forecasts ($m), 2014–2020
Table 11: Karenitecin, Ovarian Cancer, Spain, Sales Forecasts ($m), 2014–2020
Table 12: Karenitecin, Ovarian Cancer, Japan, Sales Forecasts ($m), 2014–2020

1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($bn), 2010–2020
Figure 3: Ovarian Cancer, Worldwide, Incidence (million), 2008-2030
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030
Figure 5: Ovarian Cancer, Worldwide, Mortality (million), 2008-2030
Figure 6: Broad Classification of Ovarian Cancer
Figure 7: Classification of Ovarian Cancer
Figure 8: Drug Model Diagram of Karenitecin
Figure 9: Karenitecin, Ovarian Cancer, Global, Sales Forecasts ($m), 2014–2020
Figure 10: Karenitecin, Ovarian Cancer, The US, Sales Forecasts ($m), 2014–2020
Figure 11: Karenitecin, Ovarian Cancer, The UK, Sales Forecasts ($m), 2014–2020
Figure 12: Karenitecin, Ovarian Cancer, France, Sales Forecasts ($m), 2014–2020
Figure 13: Karenitecin, Ovarian Cancer, Germany, Sales Forecasts ($m), 2014–2020
Figure 14: Karenitecin, Ovarian Cancer, Italy, Sales Forecasts ($m), 2014–2020
Figure 15: Karenitecin, Ovarian Cancer, Spain, Sales Forecasts ($m), 2014–2020
Figure 16: Karenitecin, Ovarian Cancer, Japan, Sales Forecasts ($m), 2014–2020
Figure 17: Karenitecin , Ovarian Cancer, Sales Distribution (%), By Country, 2020
Figure 18: Patients Approved for the Drug
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/2114412

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Nov 24, 2014
8:19:41 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020

Web Address

http://www.researchandmarkets.com/reports/2114412

Office Code

SCOI7T

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Site License USD 4,000
Electronic (PDF) - Single User USD 2,000
Electronic (PDF) - Enterprisewide USD 6,000

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Nov 24, 2014
8:19:41 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)